Drug intelligence / Profile preview

recombinant new coronavirus protein vaccine

Development stage: Unknown
Lead developer: Novavax
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The recombinant new coronavirus protein vaccine is a pharmaceutical drug designed to prevent COVID-19. It is a recombinant protein vaccine, often produced in Chinese Hamster Ovary (CHO) cells, that aims to induce an immune response, specifically neutralizing antibodies, against the SARS-CoV-2 virus. Clinical trials are evaluating its safety and immunogenicity, including specific formulations targeting variants like Omicron BA.4/5-Delta. Some formulations of this vaccine type are already on the market, indicating approval in certain regions. The vaccine is administered intramuscularly.

Other names: recombinant novel coronavirus protein vaccine (CHO cell)Omicron-Delta variant vaccine (CHO Cell)Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)Recombinant novel coronavirus protein vaccine (CHO cells)

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on recombinant new coronavirus protein vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant new coronavirus protein vaccine.

Explore the full profile